Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

Ricky Harminder Bhogal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5053-7979; OpenAlex author ID A5063435138. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 16

  1. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. Co-author DOI 10.3390/cancers18101597↗
  2. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  3. Delayed surgery during the Covid-19 pandemic did not affect long-term outcomes of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2024.102169↗
  4. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  5. Rethinking resectability: the case for neoadjuvant treatment in resectable pancreatic cancer. First author DOI 10.21037/hbsn-2025-550↗
  6. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  7. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  8. Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/as9.0000000000000486↗
  9. Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers16020452↗
  10. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  11. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053↗
  12. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  13. Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series. Last author DOI 10.3390/cancers14194678↗
  14. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  15. Coronavirus Disease 2019 Pandemic: Potential Collateral Damage on Patients With Operable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001594↗
  16. Open and Minimal Approaches to Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2020/4162657↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kai Tai Derek Yeung · 4 shared papers, 2024–2026 · strength 1.28
  2. David Cunningham · 3 shared papers, 2024–2026 · strength 0.74
  3. Keith John Roberts · 4 shared papers, 2021–2025 · strength 0.51
  4. Long R. Jiao · 2 shared papers, 2024 · strength 0.51
  5. Katharine L. Aitken · 2 shared papers, 2024–2026 · strength 0.46
  6. Stephanos Pericleous · 2 shared papers, 2020 · strength 0.43
  7. Bilal A. Al-Sarireh · 3 shared papers, 2021–2025 · strength 0.39
  8. Duncan R.C. Spalding · 3 shared papers, 2021–2025 · strength 0.36
  9. Somaiah Aroori · 3 shared papers, 2021–2025 · strength 0.36
  10. Adam Enver Frampton · 3 shared papers, 2021–2025 · strength 0.36
  11. Andreas A. Prachalias · 2 shared papers, 2021–2025 · strength 0.32
  12. Krishna V Menon · 2 shared papers, 2021–2025 · strength 0.32
  13. Alberto Porcu · 2 shared papers, 2023–2025 · strength 0.28
  14. Thomas Brendon Russell · 2 shared papers, 2023–2025 · strength 0.28
  15. Fabio Ausania · 2 shared papers, 2023–2025 · strength 0.28
  16. Ismael Domínguez-Rosado · 2 shared papers, 2023–2025 · strength 0.28
  17. Dhanny Gomez · 2 shared papers, 2023–2025 · strength 0.28
  18. Brian Ritchie Davidson · 2 shared papers, 2023–2025 · strength 0.28
  19. Manuel Maglione · 2 shared papers, 2023–2025 · strength 0.28
  20. Peter Lawrence Zaki Labib · 2 shared papers, 2023–2025 · strength 0.28
  21. Andrew Malvern Smith · 2 shared papers, 2023–2025 · strength 0.28
  22. Zaed Z. R. Hamady · 2 shared papers, 2023–2025 · strength 0.28
  23. Daniel Gerald Croagh · 2 shared papers, 2023–2025 · strength 0.28
  24. Elizabeth Pando Rau · 2 shared papers, 2023–2025 · strength 0.28
  25. Albasheer Hamadalnile · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.